References of "LUTTERI, Laurence"
     in
Bookmark and Share    
See detailEvaluation of the new Elisa CCp assay on unicap 100
Lutteri, Laurence ULg; Malaise, Michel ULg; Chapelle, Jean-Paul ULg

Poster (2005, October 27)

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailDiscovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach.
De Seny, Dominique ULg; Fillet, Marianne ULg; Meuwis, Marie-Alice ULg et al

in Arthritis and Rheumatism (2005), 52(12), 3801-12

OBJECTIVE: To identify serum protein biomarkers specific for rheumatoid arthritis (RA), using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology ... [more ▼]

OBJECTIVE: To identify serum protein biomarkers specific for rheumatoid arthritis (RA), using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology. METHODS: A total of 103 serum samples from patients and healthy controls were analyzed. Thirty-four of the patients had a diagnosis of RA, based on the American College of Rheumatology criteria. The inflammation control group comprised 20 patients with psoriatic arthritis (PsA), 9 with asthma, and 10 with Crohn's disease. The noninflammation control group comprised 14 patients with knee osteoarthritis and 16 healthy control subjects. Serum protein profiles were obtained by SELDI-TOF-MS and compared in order to identify new biomarkers specific for RA. Data were analyzed by a machine learning algorithm called decision tree boosting, according to different preprocessing steps. RESULTS: The most discriminative mass/charge (m/z) values serving as potential biomarkers for RA were identified on arrays for both patients with RA versus controls and patients with RA versus patients with PsA. From among several candidates, the following peaks were highlighted: m/z values of 2,924 (RA versus controls on H4 arrays), 10,832 and 11,632 (RA versus controls on CM10 arrays), 4,824 (RA versus PsA on H4 arrays), and 4,666 (RA versus PsA on CM10 arrays). Positive results of proteomic analysis were associated with positive results of the anti-cyclic citrullinated peptide test. Our observations suggested that the 10,832 peak could represent myeloid-related protein 8. CONCLUSION: SELDI-TOF-MS technology allows rapid analysis of many serum samples, and use of decision tree boosting analysis as the main statistical method allowed us to propose a pattern of protein peaks specific for RA. [less ▲]

Detailed reference viewed: 66 (9 ULg)
See detailDiscovery of new rheumatoid arthritis biomarkers using SELDI-TOF-MS ProteinChip approach
de Seny, D. M.; Fillet, Marianne ULg; Meuwis, Marie-Alice ULg et al

in Arthritis and Rheumatism (2004, September), 50(9, Suppl. S), 124

Detailed reference viewed: 33 (11 ULg)
See detailAssociation between lipoprotein (A) and cardiac troponins in PTCA patients
Lutteri, Laurence ULg; Legrand, Victor ULg; Gielen, J. et al

Poster (2001, May)

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailRelationship between lipoprotein (a) and cardiac troponins in PTCA patients
Lutteri, Laurence ULg; Legrand, Victor ULg; Gielen, Jacques et al

in Acta Clinica Belgica (2001), 56

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailAssociation between lipoprotein (A) and cardiac troponins in PTCA patients
Lutteri, Laurence ULg; Legrand, Victor ULg; Gielen, Jacques et al

in Clinical Chemistry & Laboratory Medicine (2001), 39(suppl), 278

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailHomocysteine et risque cardio-vasculaire
Lutteri, Laurence ULg; Chapelle, Jean-Paul ULg; Gielen, Jean-Louis ULg

in Revue Médicale de Liège (1999), 54(6), 541-7

Homocystinuria is an uncommon genetic disease characterized by a marked increase of serum homocysteine (HCY), an intermediate of methionine metabolism. In patients with homocystinuria ... [more ▼]

Homocystinuria is an uncommon genetic disease characterized by a marked increase of serum homocysteine (HCY), an intermediate of methionine metabolism. In patients with homocystinuria, hyperhomocysteinemia promotes the development of atherosclerotic lesions and is responsible for premature coronary artery disease. Recently, several studies have also demonstrated that moderate hyperhomocysteinemia--not necessarily linked to an inborn metabolic defect--may also be considered as an independant risk factor for cardiovascular disease. The main mechanisms of HCY atherogenic action are thought to be LDL oxydation, inhibition of vascular endothelium growth combined with stimulation of smooth muscular cells proliferation, and interference with the coagulation and fibrinolytic systems. Cofactors of key enzymes in HCY metabolism, folic acid, vitamin B12 and vitamin B6, may be given, alone or in combination, for the treatment of hyperhomocysteinemia. Homocysteinemia can be assessed by basal plasma HCY concentration and/or by HCY levels measured after a methionine loading test. Mainly measured till now in specialized laboratories using rather complex techniques (HPLC, GCMS, amino acid analyser ...), HCY determination is today spreading widely owing to the development of automated immunoassays. [less ▲]

Detailed reference viewed: 30 (1 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the homocysteine assay on the Abbott IMx
Chapelle, Jean-Paul ULg; Lutteri, Laurence ULg; Gielen, J.

in Clinical Chemistry (1999), 45(6), 134

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailDetermination of total homocysteine in plasma by automated fluorescence polarization immunoassay
Chapelle, Jean-Paul ULg; Gielen, Jacques; Legrand, Victor ULg et al

in Clinical Chemistry & Laboratory Medicine (1999), 37(suppl), 373

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailAn association demonstrated between homocysteine, CRP and troponin levels in PTCA patients
Lutteri, Laurence ULg; Chapelle, Jean-Paul ULg; Gielen, Jacques

in Acta Clinica Belgica. Supplementum (1999), (suppl.1), 15

Detailed reference viewed: 8 (0 ULg)